We are live on
!
Find out more
NMC
NEA Management Company Portfolio holdings
AUM
$1.76B
1-Year Est. Return
223.33%
This Fund
S&P 500
This Quarter
Est. Return
+19.36%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.31B
AUM Growth
-$137M
(-9.4%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-20.53%
Top 10 Holdings %
Top 10 Hldgs %
64.88%
Holding
54
New
1
Increased
4
Reduced
9
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Phathom Pharmaceuticals
PHAT
|
+$14.7M |
| 2 |
X4 Pharmaceuticals
XFOR
|
+$5.57M |
| 3 |
Black Diamond Therapeutics
BDTX
|
+$2.04M |
| 4 |
RGLS
Regulus Therapeutics
RGLS
|
+$667K |
| 5 |
DM
Desktop Metal, Inc.
DM
|
+$17.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IonQ
IONQ
|
+$89.9M |
| 2 |
Cloudflare
NET
|
+$77M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$53.2M |
| 4 |
ACLX
Arcellx
ACLX
|
+$38.2M |
| 5 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
+$15.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.63% |
| 2 | Consumer Staples | 12.79% |
| 3 | Industrials | 7.44% |
| 4 | Technology | 2.55% |
| 5 | Communication Services | 0.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Coursera
COUR
$1.72B
| $168M | 12.79% |
12,867,769
| – | – |
|
|
ACLX
2
DELISTED
Arcellx
ACLX
| $118M | 9.04% |
3,745,262
-1,000,000
| -21% | -$38.2M |
|
|
VRNA
3
DELISTED
Verona Pharma
VRNA
| $118M | 9.01% |
5,108,563
-476,190
| -9% | -$10.2M |
|
4
CRISPR Therapeutics
CRSP
$4.64B
| $89.1M | 6.8% |
1,587,854
| – | – |
|
5
Savara
SVRA
$1.08B
| $77.1M | 5.89% |
24,137,931
| – | – |
|
6
Geron
GERN
$905M
| $68.5M | 5.23% |
21,347,838
| – | – |
|
|
7
Mirum Pharmaceuticals
MIRM
$6.72B
| $56.6M | 4.32% |
2,186,243
-2,000,000
| -48% | -$53.2M |
|
|
BGRY
8
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
| $53.8M | 4.11% |
38,183,023
| – | – |
|
9
Monte Rosa Therapeutics
GLUE
$1.85B
| $52.7M | 4.02% |
7,692,298
| – | – |
|
10
Rhythm Pharmaceuticals
RYTM
$7.4B
| $48M | 3.66% |
2,909,956
| – | – |
|
11
Aurinia Pharmaceuticals
AUPH
$1.92B
| $38.4M | 2.93% |
3,969,834
| – | – |
|
12
CVRx
CVRX
$132M
| $36.6M | 2.79% |
2,370,542
| – | – |
|
|
NEUE
13
DELISTED
NeueHealth
NEUE
| $33.3M | 2.54% |
2,726,917
-3
| -0% | -$40 |
|
|
14
X4 Pharmaceuticals
XFOR
$375M
| $29.1M | 2.22% |
499,560
+108,334
| +28% | +$5.57M |
|
|
OKUR
15
OnKure Therapeutics
OKUR
$159M
| $28.3M | 2.16% |
478,549
| – | – |
|
16
Trevi Therapeutics
TRVI
$2.6B
| $27.2M | 2.07% |
11,370,376
| – | – |
|
|
ALLK
17
DELISTED
Allakos
ALLK
| $26.8M | 2.05% |
6,147,260
| – | – |
|
|
DM
18
DELISTED
Desktop Metal, Inc.
DM
| $25.5M | 1.95% |
1,440,759
+866
| +0.1% | +$17.4K |
|
19
NextNav
NN
$1.77B
| $24.1M | 1.84% |
8,189,156
| – | – |
|
|
20
Black Diamond Therapeutics
BDTX
$98M
| $22.5M | 1.72% |
4,448,757
+1,000,000
| +29% | +$2.04M |
|
|
21
Phathom Pharmaceuticals
PHAT
$933M
| $18.3M | 1.4% |
+1,276,595
| New | +$14.7M |
|
|
ZFOX
22
DELISTED
ZeroFox Holdings, Inc. Common Stock
ZFOX
| $18.1M | 1.38% |
18,068,513
| – | – |
|
|
ADAP
23
DELISTED
Adaptimmune Therapeutics
ADAP
| $15.8M | 1.21% |
17,079,778
-1
| -0% | -$1 |
|
|
INZY
24
DELISTED
Inozyme Pharma
INZY
| $13.6M | 1.04% |
2,437,689
| – | – |
|
25
Celcuity
CELC
$3.99B
| $12.7M | 0.97% |
1,250,001
| – | – |
|
Similar funds
NM
SLF
CCIA
SW
CGH
PWP
CIP
KOCAA
NEA Management Company's Q2 2023 Portfolio in Review
As of Q2 2023, NEA Management Company held 54 positions worth $1.31B, down 9.4% from $1.45B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
NEA Management Company withdrew a net $269M in Q2 2023, closing 10 positions and reducing 9 holdings. Its most notable exit was IonQ, an estimated $89.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 67% a quarter earlier, followed by Consumer Staples and Industrials.
Against the trend, NEA Management Company opened a new position in Phathom Pharmaceuticals worth $18.3M.
- NEA Management Company's largest Q2 2023 buy was Phathom Pharmaceuticals: 1,276,595 shares worth $18.3M.
- NEA Management Company added most to X4 Pharmaceuticals in Q2 2023, an estimated $5.57M increase.
- NEA Management Company's biggest Q2 2023 reduction was Mirum Pharmaceuticals, cutting an estimated $53.2M.
- NEA Management Company fully exited IonQ in Q2 2023, selling an estimated $89.9M.
- NEA Management Company's ten largest holdings make up 65% of its $1.31B portfolio in Q2 2023.
- NEA Management Company opened 1 new position and closed 10 in Q2 2023.
- NEA Management Company's portfolio value fell 9.4% quarter-over-quarter to $1.31B.
Based on NEA Management Company's 13F filing for Q2 2023, filed 11 Aug 2023.